Search Result

Results for "

complement protein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Complement System (16) Akt (2) Amino Acid Derivatives (1) Apoptosis (2) Biochemical Assay Reagents (7) Caspase (1) CD38 (2) DNA/RNA Synthesis (1) Endogenous Metabolite (2) Fluorescent Dye (1) HSV (1) Liposome (1) mRNA (1) mTOR (1) Orthopoxvirus (1) Phosphoramidites (1) Small Interfering RNA (siRNA) (1) TGF-β Receptor (1) VEGFR (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (4) Endocrinology (2) Infection (4) Inflammation/Immunology (11) Metabolic Disease (5) Neurological Disease (4)
Oligonucleotides:	Liposome (2) mRNA (1) siRNA drugs (2) Other Phosphoramidite (2) Phosphoramidites (2) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: Complement System

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9976

Isatuximab 1 Publications Verification ch38SB19; hu38SB19; SAR-650984	CD38 Apoptosis	Cancer
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .

HY-A0183

Phosphatidylserine 1 Publications Verification Phospholipids, phosphatidylserines; Serine glycerophosphatides	Akt TGF-β Receptor	Inflammation/Immunology
Phosphatidylserine (Phospholipids) is a well-conserved anti-inflammatory and immunosuppressive signal. Phosphatidylserine is involved in membrane translocation and the activation of protein kinase C, participating in Akt signaling through its interaction with PIP3. The local exposure of Phosphatidylserine can interact with complement and other proteins, promoting microglial phagocytosis during critical periods of synaptic refinement. Phosphatidylserine can promote blood coagulation in the extracellular environment and acts as a "eat me" signal to clear out apoptotic cells. Phosphatidylserine can suppress inflammation in tissues by inducing TGF-β secretion and inhibiting immune responses .

HY-NP004

Cobra Venom Factor CVF	Complement System	Inflammation/Immunology
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) .

HY-134222A

N-Acetylserine N-Acetyl-L-serine	Endogenous Metabolite Complement System	Others
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third *complement* protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification .

HY-P99050

Sutimlimab BIVV009; IPN-009; TNT009	Complement System	Cardiovascular Disease Inflammation/Immunology
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .

HY-P99365

Ravulizumab ALXN1210	Complement System	Metabolic Disease
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .

HY-NP0194A

C1q Protein (mouse)	Complement System	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology
C1q Protein (mouse) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (mouse) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease .

HY-P11329

GFP11	Fluorescent Dye	Others
GFP11 is a protein fusion tag consisting of 16 amino acids. When GFP11 and GFP1-10 are sufficiently close in physical space, they undergo spontaneous, irreversible complementation to reassemble into an intact, functional GFP protein that emits green fluorescence. GFP11 can be used to form a split GFP system for high-throughput biotechnology and flow cytometry applications .

HY-153229

Firefly luciferase mRNA-LNP 1 Publications Verification	mRNA Biochemical Assay Reagents	Others
Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency .

HY-P99905

Efdamrofusp alfa 1 Publications Verification IBI302	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-145720

Cemdisiran ALN-CC5	Complement System Small Interfering RNA (siRNA)	Metabolic Disease
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .

HY-P10633

SmBiT Tag	Amino Acid Derivatives	Others
SmBiT Tag is an 11-amino-acid short peptide with extremely low natural affinity for LgBiT, with a K_d value of approximately 190 μM. It serves as a core component of the NanoLuc Binary Technology (NanoBiT) system. NanoBiT is a bioluminescent reporter system based on protein fragment complementation technology, which is used to monitor dynamic protein-protein interactions in live cells and in vitro .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38 Apoptosis	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody that targets the transmembrane receptor and extracellular enzyme CD38, a protein highly expressed in hematological malignancies, including multiple myeloma. Isatuximab (anti-CD38) exhibits anti-tumor activity through multiple biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and non-crosslinking direct induction of apoptosis. Isatuximab (anti-CD38) also directly inhibits the extracellular enzyme activity of CD38, which is related to many cellular functions .

HY-P99638

Gefurulimab ALXN-1720	Complement System	Inflammation/Immunology
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-P1345A

TLQP-21 TFA 2 Publications Verification	Complement System	Neurological Disease Endocrinology
TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .

HY-128342

Complement C5-IN-1 1 Publications Verification	Complement System	Inflammation/Immunology
Compound C5-IN-1 (Compound 7) is a selective allosteric inhibitor of complement component protein C5. Compound C5-IN-1 prevents C5 from being cleaved by C5 convertase, inhibits the cleavage of C5 into C5a and C5b, and thus blocks the formation of membrane attack complex (MAC). Compound C5-IN-1 has an IC₅₀ of 0.77 μM and 5 nM in 50% human whole blood and 2% human serum to block MAC deposition induced by zymosan, respectively. Compound C5-IN-1 can be used to study diseases related to complement overactivation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .

HY-NP0194C

C1q Protein (rat)	Complement System	Inflammation/Immunology
C1q Protein (rat) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rat) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune and non-immune cells. C1q Protein (rat) can be used for the research of mutiple disease .

HY-145720A

Cemdisiran sodium ALN-CC5 sodium	Complement System	Others
Cemdisiran sodium is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.

HY-P991067

Vensobafusp alfa KP-104	Complement System	Inflammation/Immunology
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .

HY-P1345

TLQP-21	Complement System	Neurological Disease Endocrinology
TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor 1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .

HY-153405

Activated DPG Subunit	Biochemical Assay Reagents Phosphoramidites	Others
Activated DPG Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153406

Activated T Subunit	Biochemical Assay Reagents	Others
Activated T Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. Activated T subunit can be used for research of muscular dystrophy .

HY-P99767

Olendalizumab ALXN1007; Lendalizumab	Complement System	Infection
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (K_i=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .

HY-NP0194B

C1q Protein (rabbit)	Complement System	Inflammation/Immunology
C1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease .

HY-P2969

Complement factor I	Endogenous Metabolite	Metabolic Disease
Complement factor I is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46) .

HY-153403

Activated A Subunit	Biochemical Assay Reagents	Others
Activated A Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153404

Activated C Subunit	DNA/RNA Synthesis	Others
Activated C Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153407

NCP2 Anchor	Biochemical Assay Reagents	Others
NCP2 Anchor can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 52 jumping. NCP2 Anchor can be used for research of muscular dystrophy .

HY-153230

Firefly luciferase circRNA-LNP	Liposome Biochemical Assay Reagents	Others
Firefly luciferase circRNA-LNP is a lipid nanoparticle (LNP) containing Firefly luciferase circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. Luciferase is commonly used as a bioluminescent reporter gene for gene regulation and function studies. Firefly Luciferase circRNA will express firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Common luciferase are firefly luciferase and sea kidney luciferase .

HY-153406A

(rac)-Activated T subunit	Biochemical Assay Reagents	Others
(rac)-Activated T subunit is the racemate of Activated T Subunit (HY-153406). Activated T Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. (rac)-Activated T subunit can be used for research of muscular dystrophy .

HY-P11137

LANA	HSV	Cancer
LANA is a KSHV latency-associated nuclear antigen. The core function of LANA is to act as an "anchor" for the viral genome, attaching it to the chromatin of the host cell. LANA ensures that the episomal DNA of KSHV replicates together with the host chromosome and is evenly distributed among the daughter cells, thereby maintaining the latent infection of the virus in the cell population. LANA can regulate the transcription of viral and host cell genes, and regulate certain host cell genes to promote cell survival. LANA can be used to study the viral DNA tethering structure .

HY-181040

Factor B-IN-8	Complement System	Inflammation/Immunology
Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC₅₀ of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC₅₀ of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH) .

HY-P992081

Anti-H3L Antibody (NAL_A185)	Orthopoxvirus	Infection
Anti-H3L Antibody (NAL_A185) is a neutralizing antibody targeting the H3L envelope protein of vaccinia virus (CV) belonging to the genus Orthopoxvirus. By binding to the H3L protein of intracellular mature virions, Anti-H3L Antibody (NAL_A185) blocks the binding of the virus to host cells, thereby neutralizing viral infectivity. Anti-H3L Antibody (NAL_A185) not only protects BALB/c mice from intranasal challenge with the lethal vaccinia virus WR strain, reducing weight loss and mortality, but also exhibits complement-dependent neutralizing activity against monkeypox virus. Among these properties, NAL_A185 is an immune target induced by the smallpox vaccine Dryvax; it elicits a robust recall antibody response and induces high-titer neutralizing antibodies in mice. Anti-H3L Antibody (NAL_A185) can be used for studies related to vaccinia virus infection, monkeypox and monkeypox disease .

Cat. No.	Product Name

HY-L207

Mass Spectrometry Human Endogenous Metabolite Library	664 compounds
Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms. MCE can provide 664 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Mass Spectrometry Human Endogenous Metabolite Library

664 compounds

Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms.

MCE can provide 664 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

HY-L001P

Bioactive Compound Library Plus	32,710 compounds
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 32,710 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc. Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.

Bioactive Compound Library Plus

32,710 compounds

Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.

MCE owns a unique collection of 32,710 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc.

Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.

HY-L036P

Covalent Screening Library Plus	5,994 compounds
Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery. MCE covalent inhibitor library contains 5,994 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc. MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Covalent Screening Library Plus

5,994 compounds

Small molecule covalent inhibitors, or irreversible inhibitors, are a type of inhibitors that exert their biological functions by irreversibly binding to target through covalent bonds. Compared with non-covalent inhibitors, covalent inhibitors have obvious advantages in bioactivity, such that covalent warheads can target rare residues of a particular target protein, thus leading to the development of highly selective inhibitors and achieving a more complete and continued target occupancy in living systems. In recent years, the distinct strengths of covalent inhibitors in overcoming drug resistance had been recognized. However, toxicity can be a real challenge related to this class of therapeutics due to their potential for off-target reactivity and has led to these drugs being disfavored as a drug class. The drug design and optimization of covalent inhibitors has become a hot spot in drug discovery.

MCE covalent inhibitor library contains 5,994 small molecules including identified covalent inhibitors and other molecules having common covalent reactive groups as warheads, such as acrylamides, activated terminal acetylenes, sulfonyl fluorides/esters, cloracetamides, alkyl halides, epoxides, aziridines, disulfides, etc.

MCE Covalent inhibitor Library plus, with more powerful screening capability, further complement Covalent inhibitor Library (HY-L036) by adding some fragment compounds with covalent warheads.

Cat. No.	Product Name	Type

HY-NP004

Cobra Venom Factor CVF	Biochemical Assay Reagents
Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) .

Cobra Venom Factor

CVF

Biochemical Assay Reagents

Cobra Venom Factor (CVF) is a selective activator targeting complement components C3, C5, and factor B in the complement system. After binding to factor B, Cobra Venom Factor is cleaved by factor D, forming a stable C3/C5 convertase resistant to regulatory proteins H and I. This continuously hydrolyzes C3 and C5, depleting serum complement while inducing neutrophil migration, vascular leakage, and increased TNF-α levels. Cobra Venom Factor can be used to deplete complement and mimic complement activation-related pathological states, and is applied in animal models of complement-mediated diseases such as acute respiratory distress syndrome (ARDS), sepsis, and shock. Cobra Venom Factor can be isolated from the venom of cobras (e.g., Naja atra, Naja melanoleuca, Naja kaouthia, etc.) .

HY-NP0194A

C1q Protein (mouse)	Biochemical Assay Reagents
C1q Protein (mouse) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (mouse) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease .

HY-153229

Firefly luciferase mRNA-LNP 1 Publications Verification	Biochemical Assay Reagents
Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency .

Firefly luciferase mRNA-LNP

1 Publications Verification

Biochemical Assay Reagents

Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency .

HY-NP0194C

C1q Protein (rat)	Biochemical Assay Reagents
C1q Protein (rat) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rat) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune and non-immune cells. C1q Protein (rat) can be used for the research of mutiple disease .

HY-NP0194B

C1q Protein (rabbit)	Biochemical Assay Reagents
C1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease .

C1q Protein (rabbit)

Biochemical Assay Reagents

C1q Protein (rabbit) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (rabbit) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (rabbit) can be used for the research of mutiple disease .

HY-153230

Firefly luciferase circRNA-LNP	Biochemical Assay Reagents
Firefly luciferase circRNA-LNP is a lipid nanoparticle (LNP) containing Firefly luciferase circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. Luciferase is commonly used as a bioluminescent reporter gene for gene regulation and function studies. Firefly Luciferase circRNA will express firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Common luciferase are firefly luciferase and sea kidney luciferase .

Firefly luciferase circRNA-LNP

Biochemical Assay Reagents

Firefly luciferase circRNA-LNP is a lipid nanoparticle (LNP) containing Firefly luciferase circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. Luciferase is commonly used as a bioluminescent reporter gene for gene regulation and function studies. Firefly Luciferase circRNA will express firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Common luciferase are firefly luciferase and sea kidney luciferase .

Cat. No.	Product Name	Target	Research Area

HY-P11329

GFP11	Fluorescent Dye	Others
GFP11 is a protein fusion tag consisting of 16 amino acids. When GFP11 and GFP1-10 are sufficiently close in physical space, they undergo spontaneous, irreversible complementation to reassemble into an intact, functional GFP protein that emits green fluorescence. GFP11 can be used to form a split GFP system for high-throughput biotechnology and flow cytometry applications .

HY-P10633

SmBiT Tag	Amino Acid Derivatives	Others
SmBiT Tag is an 11-amino-acid short peptide with extremely low natural affinity for LgBiT, with a K_d value of approximately 190 μM. It serves as a core component of the NanoLuc Binary Technology (NanoBiT) system. NanoBiT is a bioluminescent reporter system based on protein fragment complementation technology, which is used to monitor dynamic protein-protein interactions in live cells and in vitro .

HY-P1823

C-Reactive Protein (CRP) (174-185)	Akt mTOR Caspase	Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
C-Reactive Protein (CRP) is an anti-pneumococcal plasma protein that can serve as an inflammatory marker. C-Reactive protein can protect mice from pneumococcal infection by activating complement. C-Reactive protein can inhibit the activation of caspase-3/9 through the CD64/AKT/mTOR pathway, thereby promoting chemotherapy resistance in mice with tongue squamous cell carcinoma .

HY-P1345A

TLQP-21 TFA 2 Publications Verification	Complement System	Neurological Disease Endocrinology
TLQP-21 TFA, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8μM). TLQP-21 TFA activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 TFA is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P1345

TLQP-21	Complement System	Neurological Disease Endocrinology
TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent *G-protein-coupled receptor complement-3a receptor 1 (C3aR1)* agonist (EC₅₀: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca ²⁺. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions .

HY-P11137

LANA	HSV	Cancer
LANA is a KSHV latency-associated nuclear antigen. The core function of LANA is to act as an "anchor" for the viral genome, attaching it to the chromatin of the host cell. LANA ensures that the episomal DNA of KSHV replicates together with the host chromosome and is evenly distributed among the daughter cells, thereby maintaining the latent infection of the virus in the cell population. LANA can regulate the transcription of viral and host cell genes, and regulate certain host cell genes to promote cell survival. LANA can be used to study the viral DNA tethering structure .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9976

Isatuximab 1 Publications Verification ch38SB19; hu38SB19; SAR-650984	CD38 Apoptosis	Cancer
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .

HY-P99050

Sutimlimab BIVV009; IPN-009; TNT009	Complement System	Cardiovascular Disease Inflammation/Immunology
Sutimlimab is a humanized monoclonal IgG4 antibody. Sutimlimab inhibits complement protein component 1, s subcomponent (C1s). Sutimlimab blocks C3 and C4 activation. Sutimlimab can be used for the research of cold agglutinin disease and complement-mediated hemolytic uremic syndrome .

HY-P99365

Ravulizumab ALXN1210	Complement System	Metabolic Disease
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .

HY-P99905

Efdamrofusp alfa 1 Publications Verification IBI302	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38 Apoptosis	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody that targets the transmembrane receptor and extracellular enzyme CD38, a protein highly expressed in hematological malignancies, including multiple myeloma. Isatuximab (anti-CD38) exhibits anti-tumor activity through multiple biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cell phagocytosis, and non-crosslinking direct induction of apoptosis. Isatuximab (anti-CD38) also directly inhibits the extracellular enzyme activity of CD38, which is related to many cellular functions .

HY-P99638

Gefurulimab ALXN-1720	Complement System	Inflammation/Immunology
Gefurulimab (ALXN-1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .

HY-P991067

Vensobafusp alfa KP-104	Complement System	Inflammation/Immunology
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .

HY-P99767

Olendalizumab ALXN1007; Lendalizumab	Complement System	Infection
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (K_i=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .

HY-P992081

Anti-H3L Antibody (NAL_A185)	Orthopoxvirus	Infection
Anti-H3L Antibody (NAL_A185) is a neutralizing antibody targeting the H3L envelope protein of vaccinia virus (CV) belonging to the genus Orthopoxvirus. By binding to the H3L protein of intracellular mature virions, Anti-H3L Antibody (NAL_A185) blocks the binding of the virus to host cells, thereby neutralizing viral infectivity. Anti-H3L Antibody (NAL_A185) not only protects BALB/c mice from intranasal challenge with the lethal vaccinia virus WR strain, reducing weight loss and mortality, but also exhibits complement-dependent neutralizing activity against monkeypox virus. Among these properties, NAL_A185 is an immune target induced by the smallpox vaccine Dryvax; it elicits a robust recall antibody response and induces high-titer neutralizing antibodies in mice. Anti-H3L Antibody (NAL_A185) can be used for studies related to vaccinia virus infection, monkeypox and monkeypox disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0183

Phosphatidylserine 1 Publications Verification Phospholipids, phosphatidylserines; Serine glycerophosphatides	Animals Source Classification	Akt TGF-β Receptor
Phosphatidylserine (Phospholipids) is a well-conserved anti-inflammatory and immunosuppressive signal. Phosphatidylserine is involved in membrane translocation and the activation of protein kinase C, participating in Akt signaling through its interaction with PIP3. The local exposure of Phosphatidylserine can interact with complement and other proteins, promoting microglial phagocytosis during critical periods of synaptic refinement. Phosphatidylserine can promote blood coagulation in the extracellular environment and acts as a "eat me" signal to clear out apoptotic cells. Phosphatidylserine can suppress inflammation in tissues by inducing TGF-β secretion and inhibiting immune responses .

HY-134222A

N-Acetylserine N-Acetyl-L-serine	Structural Classification Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Complement System
N-Acetylserine (N-Acetyl-L-serine) is a complement pathway modulator targeting activated third *complement* protein (C3b) and an amino-terminal residue (an N-terminal acetylation modification group). N-Acetylserine reacts with the exposed thioester group of C3b via its hydroxyl group, thereby blocking the covalent binding of glycerol to this thioester group. N-Acetylserine widely exists in soluble proteins of mammalian cells (accounting for approximately 80% of such proteins). N-Acetylserine has a blocking property that prevents direct Edman sequencing of proteins; deblocking is achievable through trifluoroacetic acid-catalyzed N→O acetyl migration followed by β-elimination. N-Acetylserine is suitable for sequencing of proteins with N-terminal acetylserine modification .

Host:	Mouse (2) Rabbit (8)
Reactivity:	Human (9) Rat (5) Mouse (6)
Application:	IHC-P (6) ICC/IF (6) IF-Tissue (1) IP (3) WB (10) FC (1) ELISA (3)
Isotype:	IgG (8) IgG1 (2)
Conjugation:	Non-conjugated (10) Biotin (10)
Clonality:	Monoclonal (9) Recombinant (6)
Modification:	Unmodified (9)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86840

	Complement C5 Antibody (YA6533) complement C5 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 complement C5 beta chain complement C5 alpha chain C5a anaphylatoxin complement C5 alpha' chain C5 CPAMD4	WB, ICC/IF, IHC-P, FC	Human
	Complement C5 Antibody (YA6533) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Complement C5.

HY-P86517

	Adiponectin Antibody (YA6209) ADIPOQ; ACDC; ACRP30; APM1; GBP28; Adiponectin; 30 kDa adipocyte complement-related protein; Adipocyte complement-related 30 kDa protein; ACRP30; Adipocyte; C1q and collagen domain-containing protein; Adipose most abundant gene transcript 1	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Adiponectin Antibody (YA6209) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Adiponectin.

HY-P85854

	Clusterin Antibody (YA5546) CLU; APOJ; CLI; KUB1; AAG4; Clusterin; Aging-associated gene 4 protein; Apolipoprotein J; Apo-J; complement cytolysis inhibitor; CLI; complement-associated protein SP-40; 40; Ku70-binding protein 1; NA1/NA2; Testosterone-repressed prostate m	WB, ICC/IF, ELISA	Human, Mouse, Rat
	Clusterin Antibody (YA5546) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Clusterin.

HY-P85894

	CD35 Antibody (YA5586) C3 binding protein; C3b/C4b receptor; C3BR; C4BR; CD 35; CD35; CD35 antigen; complement component; 3b/4b; receptor 1; Knops blood group; complement component; 3b/4b; receptor 1 including Knops blood group system; complement component receptor 1; complement receptor 1; complement receptor type 1; CR 1; CR1; CR1_HUMAN; KN; Knops blood group antigen	IHC-P, WB, ICC/IF, ELISA	Human
	CD35 Antibody (YA5586) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD35.

HY-P87306

	C4 Antibody (YA6989) Acidic C4 antibody; Acidic complement C4 antibody; Basic C4 antibody; Basic complement C4 antibody; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 2 antibody; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3 antibody; C4, Chido form antibody; C4, Rodgers from antibody; C4A anaphylatoxin antibody; C4A antibody	WB, ICC/IF, IF-Tissue, IHC-P	Human
	C4 Antibody (YA6989) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to C4.

HY-P82566

	GC1q R Antibody (YA2311) C1QBP; GC1QBP; HABP1; SF2P32; complement component 1 Q subcomponent-binding protein; mitochondrial; GC1q-R protein; Glycoprotein gC1qBP; C1qBP; Hyaluronan-binding protein 1; Mitochondrial matrix protein p32; p33	WB, IP	Human, Mouse, Rat
	GC1q R Antibody (YA2311) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GC1q R.

HY-P82566A

	GC1q R Antibody (YA2311)(PBS only) C1QBP; GC1QBP; HABP1; SF2P32; complement component 1 Q subcomponent-binding protein; mitochondrial; GC1q-R protein; Glycoprotein gC1qBP; C1qBP; Hyaluronan-binding protein 1; Mitochondrial matrix protein p32; p33	WB, IP	Human, Mouse, Rat
	GC1q R Antibody (YA2311) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GC1q R.

HY-P80004

	Adiponectin Antibody (YA639) 30 kDa adipocyte complement related protein; ACDC; ACRP 30; ACRP30; ADIPO_HUMAN; Adipocyte; AdipoQ; Adipose most abundant gene transcript 1; Adipose specific collagen like factor; ADIPQTL1; ADPN; APM 1; apM-1; ApM1; C1q and collagen domain-containing protein; GBP 28; GBP28; Gelatin binding protein; Gelatin binding protein 28; Gelatin-binding protein.	WB, ICC/IF, IHC-P	Mouse
	Adiponectin Antibody (YA639) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Adiponectin.

HY-P87145

	VSIG4 Antibody (YA6838) complement receptor of the immunoglobulin superfamily antibody; CRIg antibody; Ig superfamily protein antibody; protein Z39Ig antibody; UNQ317/PRO362 antibody; V set and immunoglobulin domain containing 4 antibody; V-set and immunoglobulin domain-containing protein 4 antibody; VSIG4 antibody; VSIG4_HUMAN antibody; Z39IG antibody;	WB, IHC-P	Human
	VSIG4 Antibody (YA6838) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VSIG4.

HY-P87278

	VDAC1/2/3 Antibody (YA6961) hVDAC1 antibody; MGC111064 antibody; Mithocondrial porin antibody; OPM2, yeast, human complement of antibody; Outer mitochondrial membrane protein porin 1 antibody; Plasmalemmal porin antibody; Porin 31 HL antibody; Porin 31 HM antibody; Porin 31HL antibody; Porin 31HM antibody	WB	Human, Mouse, Rat
	VDAC1/2/3 Antibody (YA6961) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VDAC1/2/3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-153229

Firefly luciferase mRNA-LNP 1 Publications Verification		mRNA Liposome
Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency .

HY-145720

Cemdisiran ALN-CC5		siRNAs siRNA drugs
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .

HY-145720A

Cemdisiran sodium ALN-CC5 sodium		siRNAs siRNA drugs
Cemdisiran sodium is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.

HY-153405

Activated DPG Subunit		Phosphoramidites Other Phosphoramidite
Activated DPG Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153404

Activated C Subunit		Phosphoramidites Other Phosphoramidite
Activated C Subunit can be used in the synthesis of exon jumping oligomer conjugates. The oligomer conjugates complement selected target sites in the human anti-muscular atrophy protein gene and induce exon 51 jumping. It can be used for research of muscular dystrophy .

HY-153230

Firefly luciferase circRNA-LNP		Liposome
Firefly luciferase circRNA-LNP is a lipid nanoparticle (LNP) containing Firefly luciferase circRNA, suitable for assays of RNA delivery, translation efficiency, cell viability, etc. Luciferase is commonly used as a bioluminescent reporter gene for gene regulation and function studies. Firefly Luciferase circRNA will express firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Common luciferase are firefly luciferase and sea kidney luciferase .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Human (53) Rhesus Macaque (1) Bovine (2) Rat (5) Mouse (24) Cynomolgus (8) Rabbit (1) Dog (1) Pig (2)
Tag:	SUMO (1) His (80) Tag Free (6) Avi (9) Myc (3) Fc (11)
Source:	HEK293 (73) Sf9 insect cells (1) P. pastoris (3) E. coli (20)

complement protein

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products